BR112018075395A2 - combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas - Google Patents

combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas

Info

Publication number
BR112018075395A2
BR112018075395A2 BR112018075395-5A BR112018075395A BR112018075395A2 BR 112018075395 A2 BR112018075395 A2 BR 112018075395A2 BR 112018075395 A BR112018075395 A BR 112018075395A BR 112018075395 A2 BR112018075395 A2 BR 112018075395A2
Authority
BR
Brazil
Prior art keywords
chronic
diabetes
nutra
bioenergetic
epigenetic
Prior art date
Application number
BR112018075395-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Astudillo De La Vega Horacio
Original Assignee
Astudillo De La Vega Horacio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astudillo De La Vega Horacio filed Critical Astudillo De La Vega Horacio
Priority claimed from PCT/MX2017/000061 external-priority patent/WO2017213486A2/es
Publication of BR112018075395A2 publication Critical patent/BR112018075395A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112018075395-5A 2015-06-08 2017-06-08 combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas BR112018075395A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562172339P 2015-06-08 2015-06-08
US15/176,422 US10285963B2 (en) 2015-06-08 2016-06-08 Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
US15/176,422 2016-06-08
MX2017007448A MX365886B (es) 2015-06-08 2017-06-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.
MXMX/A/2017/007448 2017-06-07
PCT/MX2017/000061 WO2017213486A2 (es) 2016-06-08 2017-06-08 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas

Publications (1)

Publication Number Publication Date
BR112018075395A2 true BR112018075395A2 (pt) 2019-04-02

Family

ID=57450744

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075395-5A BR112018075395A2 (pt) 2015-06-08 2017-06-08 combinação de reguladores metabólicos bioenergé-ticos e nutra-epigenéticos, compostos nutracêuti-cos em combinações convencionais e baseadas em na-notecnologia para reverter e prevenir a senescên-cia celular acelerada por lesão crônica causada por diabetes e outras doenças complexas crônico-degenerativas

Country Status (8)

Country Link
US (1) US10285963B2 (https=)
JP (1) JP2019521184A (https=)
CN (1) CN109890369B (https=)
BR (1) BR112018075395A2 (https=)
CA (1) CA3027048A1 (https=)
ES (1) ES2988151T3 (https=)
MX (1) MX365886B (https=)
RU (1) RU2749950C2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470060B1 (en) * 2016-06-08 2024-07-31 Astudillo De La Vega, Horacio Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
US20100209382A1 (en) * 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
JPWO2008143182A1 (ja) * 2007-05-17 2010-08-05 株式会社カネカ 甘草ポリフェノールを含有する組成物
JP5594819B2 (ja) * 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品
US8623924B2 (en) * 2011-07-15 2014-01-07 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways

Also Published As

Publication number Publication date
RU2018147077A (ru) 2020-07-10
US20160354331A1 (en) 2016-12-08
RU2749950C2 (ru) 2021-06-21
CN109890369B (zh) 2022-04-29
MX2017007448A (es) 2018-09-10
RU2018147077A3 (https=) 2020-09-21
CN109890369A (zh) 2019-06-14
CA3027048A1 (en) 2017-12-14
JP2019521184A (ja) 2019-07-25
US10285963B2 (en) 2019-05-14
MX365886B (es) 2019-06-19
ES2988151T3 (es) 2024-11-19

Similar Documents

Publication Publication Date Title
Sun et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity
Börgeson et al. Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease
Jiang et al. Butyrate improves cardiac function and sympathetic neural remodeling following myocardial infarction in rats
Vandoorne et al. Intake of a ketone ester drink during recovery from exercise promotes mTORC1 signaling but not glycogen resynthesis in human muscle
Zhang et al. Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases
Coughlan et al. AMPK activation: a therapeutic target for type 2 diabetes?
Tang et al. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase
Su et al. Mitophagy in hepatic insulin resistance: therapeutic potential and concerns
BR112015010203A8 (pt) composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina
Zhabyeyev et al. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload
Hu et al. Metformin and berberine prevent olanzapine-induced weight gain in rats
Bezerra et al. Caffeic acid phenethyl ester reduces the activation of the nuclear factor κB pathway by high-fat diet-induced obesity in mice
Marette et al. Skeletal muscle glucose metabolism and inflammation in the development of the metabolic syndrome
Totsch et al. Effects of a Standard American Diet and an anti‐inflammatory diet in male and female mice
Xu et al. Hypoglycemic and hypolipidemic effects of triterpenoid-enriched Jamun (Eugenia jambolana Lam.) fruit extract in streptozotocin-induced type 1 diabetic mice
Rolland et al. Therapeutic prospects of PPARs in psychiatric disorders: a comprehensive review
Zheng et al. 4‐O‐methylhonokiol protects against diabetic cardiomyopathy in type 2 diabetic mice by activation of AMPK‐mediated cardiac lipid metabolism improvement
Carvalho et al. Cardioprotective effects of glucose and insulin administration while maintaining normoglycemia (GIN therapy) in patients undergoing coronary artery bypass grafting
Bu et al. Blocking central galanin receptors attenuates insulin sensitivity in myocytes of diabetic trained rats
Dumortier et al. Age-dependent control of energy homeostasis by brown adipose tissue in progeny subjected to maternal diet–induced fetal programming
Lopatin Metabolic therapy in heart failure
Oliván-Viguera et al. Inhibition of intermediate-conductance calcium-activated K channel (KCa3. 1) and fibroblast mitogenesis by α-linolenic acid and alterations of channel expression in the lysosomal storage disorders, Fabry disease, and Niemann Pick C
Yorek Is fish oil a potential treatment for diabetic peripheral neuropathy?
Guo et al. Lonicerae Japonicae Flos extract and chlorogenic acid attenuates high-fat-diet-induced prediabetes via CTRPs-AdipoRs-AMPK/PPARα axes
Cao et al. Cyclocarya paliurus triterpenoids suppress hepatic gluconeogenesis via AMPK-mediated cAMP/PKA/CREB pathway

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.